Valuation
- Market cap
- 53,753,276,000
- Revenue TTM
- $7,882,920,000
- Net income TTM
- $-331,930,000
- PE ratio
- 0.00
- Forward PE
- 34.44
- Profit margin
- -4.21%
- Debt to equity
- 0.51
Trading
- Volume
- 21,700
- Avg volume
- 45,380
- Day's range
- $76.33 – $76.74
- Shares out
- 702,290,000
- Stochastic %K
- 94%
- Beta
- 1.07
- Analysts
- Strong Sell
- Price target
- $79.00
Company profile
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from c...
Show more
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Phone
- 41 61 316 81 11
- Website
- https://www.lonza.com
- Address
- Muenchensteinerstrasse 38, Basel, Switzerland
Latest news
No headlines yet.